RSNA 2019 News

Stakeholders partner for contrast-enhanced mammo trial

By AuntMinnie.com staff writers
December 2, 2019

Multiple radiology stakeholders are partnering to support the Contrast Enhanced Mammography Imaging Screening Trial (CMIST) to improve early breast cancer detection and reduce false-positive exams in women with dense breasts.

Supported by the American College of Radiology (ACR), the Breast Cancer Research Foundation (BCRF), and GE Healthcare, the trial will be managed by the ACR Center for Research and Innovation.

CMIST asks if CESM screening provides more accurate cancer detection than current screening methods in women with dense breasts
CMIST asks if CESM screening provides more accurate cancer detection than current screening methods in women with dense breasts. Image courtesy of the ACR.

CMIST seeks to determine if contrast-enhanced spectral mammography (CESM) provides more accurate cancer detection compared with a combination of digital breast tomosynthesis (DBT) and whole-breast ultrasound in women with dense breasts.

Dense breasts mask breast cancer, making it harder to detect via mammography alone. As a result, many women with dense breasts are screened with DBT and breast ultrasound. But are there other methods that work just as well? CESM combines mammography and vascular-based screening methods that highlight unusual blood flow patterns. It could be a more efficient screening approach, according to the stakeholders. In fact, early studies of CESM in women with dense breasts show an increase in breast cancer detection rate by 70% to 80% compared with conventional mammography.

The paired-design multicenter trial is expected to launch in spring 2020. The trial will evaluate the performance of CESM in screening women with mammographically dense breasts (BI-RADS density categories c and d), ages 40 to 75, at average-to-intermediate risk for breast cancer, compared with DBT and breast ultrasound.

ACR Data Science Institute posts AI algorithm list
The American College of Radiology (ACR) Data Science Institute has published a list of medical imaging artificial intelligence (AI) algorithms that have...
FDA clears GE's Clariscan macrocyclic GBCA
GE Healthcare has received U.S. Food and Drug Administration (FDA) clearance for use of the company's Clariscan macrocyclic gadolinium-based contrast...
Contrast-enhanced mammography prepares to enter clinical mainstream
Contrast-enhanced spectral mammography (CESM) is gaining momentum, and like it or not, the technique will be a part of the workup for breast imaging in...
Personalized breast cancer screening study launches
A five-year study that will investigate whether personalized approaches to breast cancer screening lead to better outcomes has launched, according to...

Copyright © 2019 AuntMinnie.com

Last Updated hh 12/2/2019 12:32:55 PM